The National Institutes of Health trial to evaluate the mpox (previously known as monkeypox) vaccine JYNNEOS has now entered the next stage and is studying the immune responses to and the safety of the vaccine in adolescents. The George Washington University is one of 18 clinical trial sites across the United States that have launched this stage testing the JYNNEOS vaccine.
A recent Houston Methodist study may offer some guidance on when certain populations should get their next booster. A research team of computational medicine and data scientists from the Houston Methodist Research Institute predicted the immune response to COVID-19 vaccines with a math model they developed, and also found that current CDC dosing intervals may require customization to protect all individuals alike.
A new study from Huntsman Cancer Institute shows HPV-related cancers are more common in young adults who previously had cancer. This data shows the importance of educating patients about the HPV vaccine – a safe and effective way to prevent cancer.
The immuno-oncology (IO) clinical trial landscape is shifting in new directions. While the number of total clinical trials is down, there are healthy signs of innovation.
A cross-cultural comparison study is the first to investigate factors that influenced the decision to get the COVID-19 vaccine in an international sample of college students from the U.S., Israel and the Czech Republic. Results provide evidence of country-specific varying perceptions of susceptibly, severity, benefits and barriers associated with a virus and vaccine.
The university is participating in the effort to determine the efficacy of what could be the first vaccine to prevent Lyme disease in children ages 5 to 17
In November 2022, the National Institute of Allergy and Infectious Diseases (NIAID) co-hosted a virtual workshop on the importance and challenges of developing mucosal vaccines for SARS-COV-2. The highlights of this workshop have now been published as a report in npj Vaccines.
New research led by the UNC Gillings School of Global Public Health shows that bivalent COVID-19 boosters are still providing effective protection from hospitalization and death, even against the most recent omicron subvariants.
Testing the efficacy of a vaccine candidate is typically a long process, with the immune response of an animal model taking around two months. A multi-institution team is developing a method that is more than an order of magnitude faster.
20240326113011.png&width=400&height=400){kind=logo}
Researchers reporting in ACS Central Science have developed a new testing platform that encapsulates B cells — some of the most important components of the immune system — into miniature “organoids” to make vaccine screening quicker and greatly reduce the number of animals needed for testing.
Researchers at Washington University School of Medicine in St. Louis have found a creative way to make a vaccine for norovirus, the leading cause of foodborne infections, by piggybacking on rotavirus, an unrelated virus for which there are already several highly effective vaccines.
Cell secretions like proteins, antibodies, and neurotransmitters play an essential role in immune response, metabolism, and communication between cells.
A study published April 11 in the Journal of the American Medical Association (JAMA) evaluated two drugs that act on the renin-angiotensin system (RAS) as potential treatments for severe COVID-19. Severe acute respiratory syndrome coronavirus2 (SARS-CoV-2), the virus that causes COVID-19, enters pulmonary and myocardial cells through binding of its spike protein to the human angiotensin-converting enzyme 2 (ACE2). ACE2 is a vital enzyme that controls blood pressure and blood flow to multiple organs, including the lungs, heart and kidneys.
Ana Fernandez-Sesma, PhD, has been appointed Chair of the Department of Microbiology at the Icahn School of Medicine at Mount Sinai. Dr. Fernandez-Sesma will direct all educational and research functions of the Department, while cultivating an academic culture that advances insights into virology, vaccinology, immunology, and microbiology, and encourages innovative approaches to teaching and mentoring.
May is Asthma and Allergy Awareness Month. Experts from the American College of Allergy, Asthma & Immunology caution that pollen season is starting earlier and lasting longer than in past decades.
South Carolina residents were more hesitant than Americans as a whole to receive the COVID-19 vaccine during the fall of 2020, report researchers in the Department of Psychiatry and Behavioral Sciences at the Medical University of South Carolina (MUSC) in the Journal of Psychiatry Research.
A team led by researchers at Weill Cornell Medicine, the University of Wisconsin-Madison; Scripps Research and the University of Chicago has identified an antibody that appears to block infection by all dominant variants of the virus that causes COVID-19, including Omicron, the most recent. Their discovery could lead to more potent vaccines and new antibody-based treatments.
After helping to develop and test new mRNA technologies for COVID-19 vaccines, University of Maryland School of Medicine (UMSOM) researchers and scientists are turning their attention to utilizing this innovative technology to ward off other infectious diseases like malaria and influenza.
Read about cutting-edge cancer research centered around elephant genes, a new clinical trial, and grants to study vaccination hesitance in the Mountain West as well as chronic lymphocytic leukemia.
People exposed to higher levels of air pollution before the pandemic had lower antibody responses to COVID-19 vaccines, according to a study led by the Barcelona Institute for Global Health (ISGlobal), an institution supported by “la Caixa” Foundation, in collaboration with the Germans Trias i Pujol Research Institute (IGTP).
Missing crucial doses of medicines and vaccines could become a thing of the past thanks to Rice University bioengineers’ next-level technology for making time-released drugs.
A study by researchers at Washington University School of Medicine in St. Louis shows that vaccinating people with updated boosters as new variants of the virus that cause COVID-19 emerge could shore up population immunity even as the virus mutates, and thereby prevent another deadly COVID-19 wave.
A new study led by Worcester Polytechnic Institute (WPI) brings into sharper focus the structural details of the COVID-19 virus, revealing an elliptical shape that “breathes,” or changes shape, as it moves in the body.
Research by the Milner Centre for Evolution at the University of Bath, UK, along with colleagues at Universities of Oxford and Aberdeen, finds that trust in scientists has hugely increased overall since the COVID-19 pandemic, but that attitudes have also become more polarized. The study also found that people were more likely to take the COVID-19 vaccine if their trust in the science had increased.
Researchers found that, despite being heavily immunocompromised, haematology patients generate strong cellular immune responses against SARS-CoV-2 after vaccination, on par with that of healthy individuals.
The seasonal flu vaccine is less effective in some years than others. New St. Jude research showed one reason behind this lack of efficacy is the inclusion of flu strains with an unstable viral protein.
Recordings of media briefings will be posted by 10 a.m. Eastern Time on each day. Watch recorded media briefings at: www.acs.org/ACSSpring2023briefings.
From septic shock to sticker shock. Keep up with this ever-growing, changing sector. Below are some of the latest stories on healthcare on Newswise.
A team of scientists from the Renaissance School of Medicine (RSOM) at Stony Brook University have identified a distinct role of retinoic acid, a metabolite of vitamin A, during the immune response of the gut.
In addition to an antigen, many vaccines also contain substances, called adjuvants, which stimulate the immune system. By using computer-aided molecular design and machine learning, a Chinese research team has now developed two novel broad-spectrum adjuvants that can significantly amplify the immune response to vaccines.
Needles are an uncomfortable but necessary aspect of vaccination. But today, scientists report steps toward an alternative, relatively painless method that can deliver biological materials to cells by “shooting” them in with air. They will present their results at ACS Spring 2023.
Booster vaccinations against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are being promoted worldwide to counter the coronavirus disease 2019 (COVID-19) pandemic.
In a study published in the journal Immunity, researchers describe a distinct and novel subset of memory B cells that predict long-lived antibody responses to influenza vaccination in humans.
UC San Diego researchers describe why SARS-CoV-2 subvariants spread more rapidly than the original virus strain, and how an early treatment might have made people more susceptible to future infections.
Below is a brief roundup of news and story ideas from the experts at UCLA Health. For more information on these stories or for help on other stories, please contact us at [email protected].
A UCLA-led team has developed an inexpensive, universal oral COVID-19 vaccine that prevented severe respiratory illness and weight loss when tested in hamsters, which are naturally susceptible to SARS-CoV-2. It proved as effective as vaccines administered by injection or intranasally in the research. If ultimately approved for human use, it could be a weapon against all COVID-19 variants and boost uptake, particularly in low- and middle-income countries, and among those with an aversion to needles.
Staphylococcus aureus, Clostridioides difficile, Candida auris, Drug-resistant Shigella. These bacteria not only have difficult names to pronounce, but they are also difficult to fight off. These bacteria may infect humans and animals, and the infections they cause are harder to treat than those caused by non-resistant bacteria. Antimicrobial resistance is an urgent global public health threat.
New research from Leela Nageswaran, assistant professor of operations management in the University of Washington Foster School of Business, considers whether individuals should be able to select their vaccine type.
A Kaiser Permanente study confirms the benefit of nirmatrelvir-ritonavir, also known as Paxlovid, as an early-stage treatment to prevent hospitalization for people with mild to moderate COVID-19, regardless of prior immunity or age. The study was published March 15, 2023, in Lancet ID.
Research is shedding light on why ‘breakthrough’ Omicron infections occur in vaccinated individuals and suggests those who are both vaccinated and experienced previous infection have better protection against getting sick again.
A group of researchers have used the Advanced Photon Source to look at monoclonal antibodies to subvert the “shield” of the Lassa virus, potentially paving the way for new therapies.
Trust in information given out by the government on cancer fell sharply among the Black population, by almost half, during the COVID-19 pandemic findings of a national US study have shown.
It's sleep awareness week, according to the National Sleep Foundation. It’s important to understand how sleep deprivation can impact your health. Most people recognize that if they don’t get enough sleep, their mood and memory will suffer the next day.
A new software tool developed by Texas Biomedical Research Institute and collaborators can help scientists and vaccine developers quickly edit genetic blueprints of pathogens to make them less harmful. The tool, called CoDe – short for Codon Deoptimization – enables users to make precise edits to a genetic code to make genes less functional – in other words, to deoptimize the genes.
Sleeping fewer than six hours per night around the time of vaccination was associated with a robust decrease in antibody response, researchers found.
In reviewing data from previous studies, a team lead by researchers at the University of Chicago and the French National Institute of Health and Medical Research (Inserm) found that individuals who had fewer than six hours of sleep per night in the days surrounding vaccination had a blunted antibody response. That indicates efforts to promote heathy sleep duration ahead of an immunization could be an easy way to improve vaccine effectiveness.
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right
